Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium

• US 20040176336A1
• Filed: 03/17/2004
• Published: 09/09/2004
• Est. Priority Date: 03/21/2000
• Status: Abandoned Application

• Current Assignee: Gustavo C. Rodriguez
• Original Assignee: Gustavo C. Rodriguez
• Inventors: Rodriguez, Gustavo C.
• Application Number:
  US10/802,273
• Publication Number:
  US 20040176336A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer. Enhanced HRT and OCP regimens and formulations are also disclosed.

Claims

1. A hormonal regimen wherein at least one of the daily dosages comprises at least 0.5 mg of norgestimate and an estrogen component which does not exceed 35 mcg EE equivalent.